{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.04","upperLimit":"7.46","value":"5.36"},{"groupId":"OG001","lowerLimit":"3.09","upperLimit":"5.52","value":"4.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"87"}],"units":"Participants"}],"title":"Participant PD-L1 expression >=1%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.68","upperLimit":"5.36","value":"3.94"},{"groupId":"OG001","lowerLimit":"3.71","upperLimit":"5.72","value":"4.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"276"},{"groupId":"OG001","value":"299"}],"units":"Participants"}],"title":"Participant PD-L1 expression <1%"}],"denoms":[{"counts":[{"groupId":"OG000","value":"370"},{"groupId":"OG001","value":"386"}],"units":"Participants"}],"description":"Quantifiable PD-L1 expression=percent of tumor cell membrane staining in a minimum of 100 evaluable tumor cells per Dako PD-L1 IHC assay. If the PD-L1 staining could not be quantified it was classified as: indeterminate=tumor cell membrane staining hampered for reasons attributed to biology of tumor biopsy specimen and not due to improper sample preparation or handling; not evaluable=tumor biopsy specimen was not optimally collected or prepared. Not evaluable determined from H\\&E process before the tumor biopsy specimen was sent for evaluation or from H\\&E process during PD-L1 evaluation; baseline PD-L1 expression=if more than one tumor biopsy specimen was available, the most recently collected specimen with a quantifiable result. If all specimens for a given participant are either indeterminate or not evaluable, then the PD-L1 expression was considered indeterminate as long as at least one specimen is indeterminate. Otherwise, PD-L1 expression was considered not evaluable.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab at 3 mg/kg solution provided intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.","id":"OG000","title":"Nivolumab"},{"description":"Everolimus provided in 10 mg tablets by mouth daily until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends.","id":"OG001","title":"Everolimus"}],"paramType":"MEDIAN","populationDescription":"PD-L1 quantifiable participants; All randomized participants with quantifiable PD-L1 expression at baseline","reportingStatus":"POSTED","timeFrame":"Randomization to date of death or date of last contact for patients without documentation of death, up to May 2015 (approximately 30 months)","title":"Overall Survival (OS) by Programmed Death-Ligand 1 (PD-L1) Expression Level","type":"SECONDARY","unitOfMeasure":"months"}